1. South Korea Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Seegene, Inc.

Seegene, Inc.

KKRX:096530
33,850.00
KRW
-600.00
(-1.74%)
1,177.08EPS
18.60P/E
995.39BMarket Cap
Nov 06Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2,405.71
1,281.11
1,269.25
1,412.29
1,706.23
1,968.48
2,345.6
10,822.46
26,465.8
16,805.17
7,687.83
8,985.41
10,285.3
10,582.42
Basic EPS, GAAP
390.36
181.82
132
136.5
62.5
206.5
513
4,831
10,359
3,586
14
-190
1,047
1,174.83
Free Cash Flow per Basic Share
-348.39
-17.59
-210.22
111.96
72.7
193.36
429.96
1,999.5
5,172.42
4,854.29
1,319.46
905.9
2,361.17
1,994.62
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
25
1,351.82
1,006.3
796.79
800.89
800.32
400.5
Book Value per Share
1,684.18
1,882.61
2,588.59
2,720.46
2,249.84
2,462.83
2,934.53
12,413.77
20,971.05
23,036.65
22,319.94
21,459.95
22,290.2
22,455.1
Tangible Book Value per Share
1,374.89
1,513.89
2,220.19
2,291.6
2,127.17
2,347.49
2,806.15
12,284.62
20,748.83
22,546.15
21,725.59
20,744.69
21,662.33
21,834.64
Basic Weighted Avg Shares
25
50
51
52
52
52
52
104
52
51
48
46
46
46
Sales/Revenue/Turnover
58,993
64,411
65,137
73,694
88,920
102,265
121,953
1,125,216
1,370,833
853,561
367,375
414,252
474,232
487,373
Operating Margin (%)
23.88
17.26
13.26
13.68
8.5
10.39
18.39
60.09
48.63
23.02
-8.18
-3.97
7.29
8.88
Depreciation Expense
3,233
5,660
6,036
6,555
6,467
7,740
10,177
16,496
35,911
57,943
65,711
71,170
70,009
68,861
Net Income, GAAP
9,573
9,141
6,774
7,123
3,257
10,728
26,672
502,281
536,559
182,139
669
-8,760
48,275
54,107
Effective Tax Rate (%)
20.15
15.31
23.98
23.92
- -
5.5
3.59
24.81
22
19.12
- -
- -
14.16
24.86
Profit Margin (%)
16.23
14.19
10.4
9.67
3.66
10.49
21.87
44.64
39.14
21.34
0.18
-2.11
10.18
11.1
Working Capital
80,342
84,789
140,260
141,043
81,326
89,804
110,300
407,578
766,810
732,312
621,333
596,394
628,030
642,760
LT Debt
25,313
26,521
43,111
45,821
787
1,807
6,267
58,525
102,806
58,464
47,204
48,745
34,412
33,393
Total Equity
84,445
94,835
135,303
142,230
117,261
128,356
152,826
646,406
1,083,596
1,150,279
1,030,399
993,054
1,015,816
1,023,381
Return on Invested Capital (%)
12.38
8.35
4.64
4.42
- -
7.95
14.83
94.4
46.23
12.03
- -
- -
2.61
2.83
Return on Capital (%)
11.18
8.76
5.22
4.68
- -
8.07
17.68
109.54
54.06
14.57
- -
- -
4.55
4.96
Return on Common Equity (%)
15.15
10.2
5.89
5.14
2.52
8.76
19.01
125.91
62.15
16.34
0.06
-0.87
4.81
5.34

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
95,793
95,521
95,811
LT Borrowings
727
232
714
LT Finance Leases
38,387
34,180
32,679
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
46
46
46
Market Capitalization
1,141,304
1,084,227
995,394

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
771,267
798,780
828,499
Cash, Cash Equivalents & STI
563,365
585,906
607,099
Accounts Receivable, Net
87,761
97,592
102,913
Inventories
87,881
82,201
80,561
Total Current Liabilities
159,620
170,751
185,740
Payables & Accruals
- -
- -
- -
ST Debt
95,793
95,521
95,811
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
40.11%
12.41%
2.29%
Free Cash Flow
100.17%
14.68%
160.67%
Net Income, GAAP
-10.73%
-443.86%
-651.11%
Sales/Revenue/Turnover
84.51%
-9.12%
14.48%
Total Cash Common Dividend
- -
507.66%
-0.06%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
89,946
100,140
108,824
115,341
414,252
2025
115,997
114,060
113,544
130,631
474,232
2026
129,139
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-45
521
36
-952.8
-190
2025
376
-2.65
315.75
107.08
1,047
2026
757.02
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
199.69
200.14
800.89
2025
- -
- -
200
199.99
800.32
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jong-Yoon Cheon
Full Time Employees
822
Sector
Health technology
Industry
Medical specialties
Address
Taewon Building Seoul SL South Korea 05548
IPO Date
Sep 10, 2010
Website
seegene.co.kr
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Seegene, Inc. (096530.KQ) develops, manufactures and markets molecular diagnostics products and automated systems for multiplex real-time PCR testing worldwide. The company offers a broad portfolio of in vitro diagnostic assays, including Allplex branded syndromic panels for respiratory infections such as influenza and respiratory syncytial virus; gastrointestinal pathogens; sexually transmitted infections and vaginitis; human papillomavirus for cervical cancer screening; tuberculosis and drug resistance; sepsis via Magicplex; and meningitis, utilizing proprietary technologies like Dual Priming Oligonucleotide (DPO), Multiple Detection Temperatures (MuDT) and its Seegene Digitalized Development System (SGDDS). Seegene provides automated platforms such as the All-in-One system encompassing STARlet-AIOS for nucleic acid extraction, PCR setup and data analysis; the fully unattended CURECA PCR system; and STARlet-AIOS for high-throughput testing, alongside instruments for point-of-care and real-time PCR. Founded in 2000 and headquartered in Seoul, South Korea, Seegene operates subsidiaries across the United States, Canada, Germany, Italy, Mexico, Brazil and the Middle East, serving hospitals, laboratories and research institutions globally with CE-IVD, Health Canada and Korean MFDS approvals. Recent developments include the unveiling of the CURECA fully automated PCR system at ADLM 2025 to advance unattended diagnostics; establishment of U.S. subsidiaries Seegene Technologies and Seegene CURECA to bolster R&D and manufacturing; a technology-sharing partnership with Werfen finalized in 2024 to form a NewCo in Spain for localized European production of syndromic PCR products; launch of Nature Awards MDx Impact Grants with Springer Nature in 2024 to fund innovative diagnostic assays; and a strategic collaboration with Microsoft announced in 2025 integrating Azure AI into SGDDS for enhanced molecular diagnostics ecosystems.